Advanced Biomed Inc. (Nasdaq: ADVB), a biotech firm specializing in the creation and marketing of cutting-edge biomedical solutions for precision medicine and enhanced diagnostics, has announced the release of its A+PerfusC™ system. This all-in-one, compact perfusion 3D cell culture incubator is engineered to simulate human physiological conditions in a lab setting.
(A+PerfusC™ 3D System-a perfusion-based 3D cell culture in a compact incubator)
The A+PerfusC™ platform combines automated perfusion with environmental regulation in a small device that can be directly mounted on a microscope for live observation. The system facilitates continuous, hands-free culture for up to 12 days, which lowers the possibility of contamination and human error. The platform encourages organoid and spheroid development by ensuring consistent nutrient supply and preventing waste buildup, which improves cell viability, growth, and the predictability of drug responses. Key features of the system include:
- 8 independent channels/patient sources per plate
- 600 tumor spheroids per row for each patient
- 4,800 tumor spheroids on each plate
- Simple transfer to 96 or 384 well plates for fast drug screening
- Easy mounting on microscopy platforms
- Expandable control platform that supports up to four incubators (in development)
The A+PerfusC™ system and its 3D culture plate (a consumable item) have undergone thorough internal testing and validation, and the design has been finalized. The company is currently working on scaling up mass production, with commercialization planned after the completion of mass production development and the establishment of quality control standards.
Potential uses include personalized oncology research, in vitro drug screening, regenerative medicine, organoid studies, and stem cell research. According to Mordor Intelligence, the global market for 3D cell cultures was valued at USD 2.32 billion in 2025 and is expected to surpass USD 4.71 billion by 2030, showing an annual compound growth rate of over 15.6%.
Dr. Yi Lu, CEO of Advanced Biomed Inc., stated, “Traditional static cell culture often results in inconsistent nutrient supply and waste accumulation, which can negatively affect cell growth, viability, and reproducibility. In high-density culture settings, especially within multi-microwell 3D culture devices, metabolic waste can quickly build up inside the micro-grooves. This necessitates more frequent medium changes, which can be labor-intensive, to maintain culture quality.”
“Our 3D culture system ensures consistent nutrient delivery and waste removal, reducing cellular stress and enhancing long-term viability. It also more accurately mimics the complexity of human tissue, which improves disease modeling and drug response predictions.”
“The company intends to scale up the A+PerfusC™ system for high-throughput applications and integrate imaging with AI-driven analytics. This aims to accelerate tumor profiling, improve cell therapy protocols, and promote the development of personalized treatments.”
About Advanced Biomed Inc.
Advanced Biomed Inc. is a holding company incorporated in Nevada that focuses on innovative biomedical technologies for precision medicine and cancer detection.
The company operates through subsidiaries in Taiwan, Hong Kong, and Mainland China. It has developed a unique microfluidic platform that combines semiconductor and biotechnology to facilitate sophisticated circulating tumor cell (CTC) detection, enrichment, and analysis. Its product line includes devices and biochips designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory approvals underway in China and plans for future global expansion.
For more information, please visit: .
Forward‑Looking Statements
This press release contains forward-looking statements, including those regarding plans, objectives, goals, strategies, future events, or performance, underlying assumptions, and other statements that are not statements of historical facts. The use of terms like “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions indicates forward-looking statements. These statements are not guarantees of future performance and involve risks and uncertainties that could cause actual results to differ significantly from the company’s expectations. These risks and uncertainties include, but are not limited to, market conditions and other factors detailed in the “Risk Factors” section of the registration statement filed with the SEC. Investors are therefore advised not to place undue reliance on these forward-looking statements. Additional factors are available in the company’s filings with the SEC. The company does not commit to updating these statements to reflect events or circumstances occurring after the date of this release.
For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email:
“`